Pfizer’s Elrexfio Meets Primary Endpoint in Phase 3 Study
Pfizer said Elrexfio met the primary endpoint in the Phase 3 MagnetisMM-32 study for RRMM.
Related stories
Nasdaq pauses volatility trading
Nasdaq announced a volatility trading pause at 11:22 a.m.
L impact | EQUITY | Oct 29, 2026, 03:27 PM UTC
Caterpillar quarterly profit beats expectations; full-year sales outlook unchanged
Caterpillar reported quarterly profit above expectations and kept its full-year sales outlook unchanged.
M impact | EQUITY | Oct 29, 2026, 03:25 PM UTC
Maxland Director Dennis Lim Acquires 100,000 Ordinary Rights
M impact | EQUITY | Oct 29, 2026, 03:25 PM UTC
Energa Milestone Removes Contract Termination Risk and Ends Monthly Penalties
Energa says a milestone achievement removes the risk of capacity market contract termination and ends monthly penalties of 1.1 million zlotys.
M impact | EQUITY | Oct 29, 2026, 03:24 PM UTC
Federal Home Loan Bank of Dallas Reports Third-Quarter 2026 Results
The bank reported third-quarter 2026 operating results.
M impact | EQUITY | Oct 29, 2026, 03:24 PM UTC
Adidas CEO Sees Possible Upside to Full-Year Revenue Guidance
Adidas CEO says there might be upside to the company's full-year revenue guidance.
M impact | EQUITY | Oct 29, 2026, 03:23 PM UTC